Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

A Vaccine (9pNGVL4aCRTE6E7L2 HPV DNA Vaccine) for the Treatment of HPV16 Positive High-Grade Cervical Intraepithelial Lesions

Trial Status: active

This phase I trial evaluates the best dose and effect of 9pNGVL4aCRTE6E7L2 HPV DNA vaccine in treating patients with HPV16 positive high-grade cervical intraepithelial lesions. 9pNGVL4aCRTE6E7L2 HPV vaccine is made of DNA and is considered as gene therapy. Gene therapy means putting a new gene into some of the cells in the body to treat a disease. 9pNGVL4aCRTE6E7L2 HPV may kill tumor cells by blocking a gene that helps cancer form and grow. Giving 9pNGVL4aCRTE6E7L2 HPV may help the immune system to recognize and attack lesions that have HPV in them.